Introducing a novel approach to targeted protein degradation, biological PROTACs (bioPROTACs) represent a promising alternative to traditional PROTACs. By engineering intracellular proteins fused with target-binding domains and E3 ubiquitin ligases, bioPROTACs offer enhanced specificity and efficacy in degrading challenging targets like KRAS and proliferating cell nuclear antigen (PCNA). This innovative technology not only provides powerful tools for understanding degradation mechanisms and target biology but also holds significant potential for therapeutic applications, offering new avenues for treating diseases by precisely modulating protein levels and functions.

bioPROTACs consist of three components in a single mRNA:

  • E3 ligase domain
  • Target protein binding domain or nanobody
  • Linker connecting both entities

Lifesensors offers unique and physiologically relevant target ubiquitination and degradation assays that allows rapid characterization of bioPROTACs for their specificity and potency.

LifeSensors helps you study the bioPROTACs to make breakthrough discoveries and pave the way to novel therapeutics​​​​​​​.

bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA)Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States
Preview our Presentation on PROTAC Drug Discovery

Advantages of Choosing LifeSensors for your PROTAC Drug Discovery

  • Study PROTAC mediated Ubiquitination and Degradation simultaneously
  • Complete suite of validation studies to establish binding, ternary complex formation, and cellular degradation
  • Experience with novel E3 ligases – ~30 E3 ligases amenable to PROTAC discovery
  • Proteomics to characterize protein degradation – establish selectivity
PROTAC Drug Discovery Services
PROTAC Drug Discovery Products